Cargando…

Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas

Aneuploidy is the hallmark of malignancy. Our previous study successfully detected nonhematogenic circulating aneuploidy cells (CACs) in types of gliomas. The current prospective clinical study aims to further precisely subcategorize aneuploid CACs, including CD31(−) circulating tumor cells (CTCs) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mingxiao, Gao, Faliang, Ren, Xiaohui, Dong, Gehong, Chen, Hongyan, Lin, Alexander Y., Wang, Daisy Dandan, Liu, Mingyang, Lin, Peter Ping, Shen, Shaoping, Jiang, Haihui, Yang, Chuanwei, Zhang, Xiaokang, Zhao, Xuzhe, Zhu, Qinghui, Li, Ming, Cui, Yong, Lin, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530864/
https://www.ncbi.nlm.nih.gov/pubmed/35940591
http://dx.doi.org/10.1111/cas.15516
_version_ 1784801776125345792
author Li, Mingxiao
Gao, Faliang
Ren, Xiaohui
Dong, Gehong
Chen, Hongyan
Lin, Alexander Y.
Wang, Daisy Dandan
Liu, Mingyang
Lin, Peter Ping
Shen, Shaoping
Jiang, Haihui
Yang, Chuanwei
Zhang, Xiaokang
Zhao, Xuzhe
Zhu, Qinghui
Li, Ming
Cui, Yong
Lin, Song
author_facet Li, Mingxiao
Gao, Faliang
Ren, Xiaohui
Dong, Gehong
Chen, Hongyan
Lin, Alexander Y.
Wang, Daisy Dandan
Liu, Mingyang
Lin, Peter Ping
Shen, Shaoping
Jiang, Haihui
Yang, Chuanwei
Zhang, Xiaokang
Zhao, Xuzhe
Zhu, Qinghui
Li, Ming
Cui, Yong
Lin, Song
author_sort Li, Mingxiao
collection PubMed
description Aneuploidy is the hallmark of malignancy. Our previous study successfully detected nonhematogenic circulating aneuploidy cells (CACs) in types of gliomas. The current prospective clinical study aims to further precisely subcategorize aneuploid CACs, including CD31(−) circulating tumor cells (CTCs) and CD31(+) circulating tumor endothelial cells, and thoroughly investigate the clinical utilities of these different subtypes of cells. Co‐detection and analysis of CTCs and circulating tumor‐derived endothelial cells (CTECs) expressing CD133, glial fibrillary acidic protein (GFAP), or epidermal growth factor receptor variant III (EGFR vIII) were performed by integrated subtraction enrichment and immunostaining fluorescence in situ hybridization (SE‐iFISH) in 111 preoperative primary diffuse glioma patients. Aneuploid CACs could be detected in most de novo glioma patients. Among detected CACs, 45.6% were CD31(−)/CD45(−) aneuploid CTCs and the remaining 54.4% were CD31(+)/CD45(−) aneuploid CTECs. Positive detection of CTECs significantly correlated with disruption of the blood–brain barrier. The median number of large CTCs ((L)CTCs, >5 μm, 2) in low‐grade glioma (WHO grade 2) was less than high‐grade glioma (WHO grades 3 and 4) (3, p = 0.044), but this difference was not observed in small CTCs ((S)CTCs, ≤5 μm), CTECs or CACs (CTCs + CTECs). The numbers of CTCs, CTECs, or CACs in patients with contrast‐enhancing (CE) lesions considerably exceeded that of non‐CE lesions (p < 0.05). Receiver operating characteristic curves demonstrated that CD31(+) CTECs, especially (L)CTECs, exhibited a close positive relationship with CE lesions. Survival analysis revealed that the high number of CD31(−) CTCs could be an adverse factor for compromised progression‐free survival and overall survival. Longitudinal surveillance of CD31(−) CTCs was suitable for evaluating the therapeutic response and for monitoring potential emerging treatment resistance.
format Online
Article
Text
id pubmed-9530864
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95308642022-10-11 Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas Li, Mingxiao Gao, Faliang Ren, Xiaohui Dong, Gehong Chen, Hongyan Lin, Alexander Y. Wang, Daisy Dandan Liu, Mingyang Lin, Peter Ping Shen, Shaoping Jiang, Haihui Yang, Chuanwei Zhang, Xiaokang Zhao, Xuzhe Zhu, Qinghui Li, Ming Cui, Yong Lin, Song Cancer Sci Original Articles Aneuploidy is the hallmark of malignancy. Our previous study successfully detected nonhematogenic circulating aneuploidy cells (CACs) in types of gliomas. The current prospective clinical study aims to further precisely subcategorize aneuploid CACs, including CD31(−) circulating tumor cells (CTCs) and CD31(+) circulating tumor endothelial cells, and thoroughly investigate the clinical utilities of these different subtypes of cells. Co‐detection and analysis of CTCs and circulating tumor‐derived endothelial cells (CTECs) expressing CD133, glial fibrillary acidic protein (GFAP), or epidermal growth factor receptor variant III (EGFR vIII) were performed by integrated subtraction enrichment and immunostaining fluorescence in situ hybridization (SE‐iFISH) in 111 preoperative primary diffuse glioma patients. Aneuploid CACs could be detected in most de novo glioma patients. Among detected CACs, 45.6% were CD31(−)/CD45(−) aneuploid CTCs and the remaining 54.4% were CD31(+)/CD45(−) aneuploid CTECs. Positive detection of CTECs significantly correlated with disruption of the blood–brain barrier. The median number of large CTCs ((L)CTCs, >5 μm, 2) in low‐grade glioma (WHO grade 2) was less than high‐grade glioma (WHO grades 3 and 4) (3, p = 0.044), but this difference was not observed in small CTCs ((S)CTCs, ≤5 μm), CTECs or CACs (CTCs + CTECs). The numbers of CTCs, CTECs, or CACs in patients with contrast‐enhancing (CE) lesions considerably exceeded that of non‐CE lesions (p < 0.05). Receiver operating characteristic curves demonstrated that CD31(+) CTECs, especially (L)CTECs, exhibited a close positive relationship with CE lesions. Survival analysis revealed that the high number of CD31(−) CTCs could be an adverse factor for compromised progression‐free survival and overall survival. Longitudinal surveillance of CD31(−) CTCs was suitable for evaluating the therapeutic response and for monitoring potential emerging treatment resistance. John Wiley and Sons Inc. 2022-08-08 2022-10 /pmc/articles/PMC9530864/ /pubmed/35940591 http://dx.doi.org/10.1111/cas.15516 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Li, Mingxiao
Gao, Faliang
Ren, Xiaohui
Dong, Gehong
Chen, Hongyan
Lin, Alexander Y.
Wang, Daisy Dandan
Liu, Mingyang
Lin, Peter Ping
Shen, Shaoping
Jiang, Haihui
Yang, Chuanwei
Zhang, Xiaokang
Zhao, Xuzhe
Zhu, Qinghui
Li, Ming
Cui, Yong
Lin, Song
Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
title Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
title_full Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
title_fullStr Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
title_full_unstemmed Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
title_short Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
title_sort nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530864/
https://www.ncbi.nlm.nih.gov/pubmed/35940591
http://dx.doi.org/10.1111/cas.15516
work_keys_str_mv AT limingxiao nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT gaofaliang nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT renxiaohui nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT donggehong nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT chenhongyan nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT linalexandery nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT wangdaisydandan nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT liumingyang nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT linpeterping nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT shenshaoping nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT jianghaihui nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT yangchuanwei nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT zhangxiaokang nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT zhaoxuzhe nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT zhuqinghui nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT liming nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT cuiyong nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas
AT linsong nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas